AZD 9272

Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: Potent and selective mGlu5 antagonist; brain penetrant
Chemical Name: 3-Fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]benzonitrile
Purity: ≥98% (HPLC)
Literature (6)

Biological Activity for AZD 9272

AZD 9272 is a potent and selective mGlu5 antagonist (IC50 values are 2.6 and 7.6 nM for rat and human receptors, respectively). Exhibits >3900-fold selectivity for mGlu5 over other mGlu receptors. Also selective over a panel of other targets. Displays discriminative effects in rats. Orally bioavailable and brain penetrant.

Technical Data for AZD 9272

M. Wt 284.22
Formula C14H6F2N4O
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 327056-26-8
PubChem ID 9838729
Smiles FC1=CC=C(C2=NOC(C3=CC(F)=CC(C#N)=C3)=N2)N=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for AZD 9272

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 14.21 50

Preparing Stock Solutions for AZD 9272

The following data is based on the product molecular weight 284.22. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 7.04 mL 35.18 mL 70.37 mL
2.5 mM 1.41 mL 7.04 mL 14.07 mL
5 mM 0.7 mL 3.52 mL 7.04 mL
25 mM 0.14 mL 0.7 mL 1.41 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for AZD 9272

References are publications that support the biological activity of the product.

Swedberg and Raboisson (2014) AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J.Pharmacol.Exp.Ther. 350 212 PMID: 24876235

Raboisson et al (2012) Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg.Med.Chem.Lett. 22 6974 PMID: 23046966

If you know of a relevant reference for AZD 9272, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Antagonists

Keywords: AZD 9272, AZD 9272 supplier, AZD9272, mGlu5, antagonists, metabotropic, glutamate, receptors, orally, bioavailable, brain, penetrant, potent, selective, Glutamate, (Metabotropic), Group, I, Receptors, 5613, Tocris Bioscience

Citations for AZD 9272

Citations are publications that use Tocris products.

Currently there are no citations for AZD 9272. Do you know of a great paper that uses AZD 9272 from Tocris? Please let us know.

Reviews for AZD 9272

There are currently no reviews for this product. Be the first to review AZD 9272 and earn rewards!

Have you used AZD 9272?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.